Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854054 | 0.86 | MAPT (0.57) | POLBMAPTGAAALDH1A1MAPK14 | |
| SCHEMBL2858371 | 0.85 | SMN1; SMN2 (0.48) | POLBMAPTGAASMN1; SMN2KDM4E | |
| SCHEMBL2853163 | 0.76 | ALDH1A1 (0.45) | POLBMAPTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL2858186 | 0.76 | KMT2A (0.48) | POLBMAPTGAAKDM4EALDH1A1 | |
| SCHEMBL2854295 | 0.76 | MAPK14 (0.68) | POLBMAPTGAAALDH1A1MAPK14 | |
| SCHEMBL2850360 | 0.75 | MAPT (0.61) | POLBMAPTGAAALDH1A1MAPK14 | |
| SCHEMBL2856280 | 0.75 | MAPK14 (0.55) | POLBMAPTGAAALDH1A1MAPK14 | |
| SCHEMBL2926984 | 0.75 | P2RX7 (0.55) | MAPTGAACNR1ALDH1A1MAPK14 | |
| SCHEMBL2079637 | 0.75 | NR4A3 (0.59) | POLBMAPTGAAHPGDALDH1A1 | |
| SCHEMBL1403169 | 0.75 | MAPT (0.54) | POLBMAPTGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | Université de Montréal (CA) | 2016-07-28 | — | — | US | disclosed |
| WO-2015042685-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | VALORISATION-RECHERCHE (CA) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213679-A1 | INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF | FBL, HNRNPA1, HNRNPUL1 | POLB 128/4885MAPT 417/4885GAA 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.